Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pediatric

With an Aging State Population, California Rheumatology Association Prepares to Increase Its Rheumatology Workforce

Linda Childers  |  October 6, 2024

The organization is supporting multiple bills and initiatives to protect and expand rheumatology care in the state.

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:California Rheumatology Alliancestate society

How to Manage Lupus Nephritis: A New Guideline Introduced

Keri Losavio  |  September 26, 2024

A new guideline, the 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis, is being introduced at ACR Convergence 2024 on Monday, Nov. 18. In the session, Lisa Sammaritano, MD, professor of clinical medicine at Weill Cornell Medicine and Hospital for Special Surgery, New York, will discuss the guideline development process and…

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2024ACR Convergence 2024 SLE

ACR on Air: A Deep Dive into Psoriatic Arthritis

Keri Losavio  |  September 26, 2024

Hosted by Jonathan S. Hausmann, MD, a pediatric and adult rheumatologist at Boston Children’s Hospital and Beth Israel Deaconess Medical Center, and an instructor in medicine at Harvard Medical School, ACR on Air debuted in 2019. In this episode, ACR Master (2016) Philip J. Mease, MD, joins Dr. Hausmann for a deep dive into psoriatic…

Filed under:American College of RheumatologyAudioConditionsPsoriatic Arthritis Tagged with:MeasePsA Resource Center

A Half-Century of Rheumatology

Vanessa Caceres  |  September 11, 2024

Celebrating its long history, the Division of Rheumatology & Immunology at Medical University of South Carolina has made strides in scleroderma, lupus and more.

Filed under:CareerMeeting Reports Tagged with:HistoryMedical University of South CarolinaSouth Carolina

Get Excited for ACR Convergence 2024

From the College  |  September 9, 2024

An engaging mix of new and returning programming is planned for ACR Convergence in Washington, D.C. “ACR Convergence is unique because of the blend of high-quality science, updates on advances in clinical care and networking opportunities to advance the field of rheumatology,” says Annual Meeting Planning Committee (AMPC) Chair Gregory C. Gardner, MD, MACP. “We…

Filed under:ACR ConvergenceMeeting Reports Tagged with:ACR Convergence 2024

FDA Approves 2 Upadacitinib Formulations for Children with pJIA & PsA

Michele B. Kaufman, PharmD, BCGP  |  August 13, 2024

Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:FDAFDA approvalpJIApolyarticular juvenile idiopathic arthritis (JIA)PsAPsA Resource CenterPsoriatic ArthritisU.S. Food and Drug Administration (FDA)upadacitinib

Summer 2024’s Awards, Appointments & Announcements in the World of Rheumatology

Gretchen Henkel  |  August 7, 2024

Dr. Megan Cooper Appointed Director of Pediatric Rheumatology & Immunology Division at WashU Megan A. Cooper, MD, PhD, a physician-scientist recognized internationally for her work in pediatric immunodeficiencies and immune dysregulation, took the reins of the Division of Pediatric Rheumatology and Immunology at Washington University School of Medicine, St. Louis, as director this past fall….

Filed under:AwardsCareer Tagged with:Dr. Julie CampbellDr. Megan A. CooperDr. Mitchell D. FormanMovers & Shakers

The Ins & Outs of Private Rheumatology Practice

Vanessa Caceres  |  July 29, 2024

For a podcast audience, Dr. Sunil Abraham shared pearls for evaluating what setting best fits you and your lifestyle, and what a career in community practice means.

Filed under:Career DevelopmentOpinionPractice SupportProfessional Topics Tagged with:ACR on AirCareerCareer developmentcommunity practicePrivate practicework-life balance

The Impact of Climate Change

Vanessa Caceres  |  July 29, 2024

Although research is still emerging, evidence suggests changes in climate, such as increases in heat, pollution and allergens, may increase the risk of flare and hospitalization in patients with rheumatoid arthritis, systemic lupus erythematosus and other rheumatic conditions. Paul Dellaripa, MD, discussed the research and how rheumatologists can help their patients.

Filed under:ConditionsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR on Airair pollutionclimate changeRheumatic Disease

FDA Approves Sarilumab for pJIA

Michele B. Kaufman, PharmD, BCGP  |  July 29, 2024

The FDA has granted sarilumab its first pediatric indication, approving the agent to treat active, polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh at least 63 kgs.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:FDA approvalpJIApolyarticular juvenile idiopathic arthritis (JIA)sarilumabU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 109
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences